Nature Reviews Gastroenterology &Hepatology最新文献_第8页

Diet-driven microbiome restoration associated with cardiometabolic benefits 饮食驱动的微生物群恢复与心脏代谢益处相关

IF 51 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-04-10 DOI: 10.1038/s41575-025-01067-7

Jordan Hindson

引用次数: 0

Metabolic diseases in the East Asian populations 东亚人群的代谢性疾病

IF 51 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-04-08 DOI: 10.1038/s41575-025-01058-8

Zhonghan Sun (, ), Yan Zheng (, )

{"title":"Metabolic diseases in the East Asian populations","authors":"Zhonghan Sun \u0000 (, ), Yan Zheng \u0000 (, )","doi":"10.1038/s41575-025-01058-8","DOIUrl":"10.1038/s41575-025-01058-8","url":null,"abstract":"East Asian populations, which account for approximately 20% of the global population, have become central to the worldwide rise of metabolic diseases over the past few decades. The prevalence of metabolic disorders, including type 2 diabetes mellitus, hypertension and metabolic dysfunction-associated steatotic liver disease, has escalated sharply, contributing to a substantial burden of complications such as cardiovascular disease, chronic kidney disease, cancer and increased mortality. This concerning trend is primarily driven by a combination of genetic predisposition, unique fat distribution patterns and rapidly changing lifestyle factors, including urbanization and the adoption of Westernized dietary habits. Current advances in genomics, proteomics, metabolomics and microbiome research have provided new insights into the biological mechanisms that might contribute to the heightened susceptibility of East Asian populations to metabolic diseases. This Review synthesizes epidemiological data, risk factors and biomarkers to provide an overview of how metabolic diseases are reshaping public health in East Asia and offers insights into biological and societal drivers to guide effective, region-specific strategies. The East Asian population is experiencing a continuous rise in metabolic disease burden. This Review provides a detailed account of epidemiological data and discusses risk factors and therapeutic approaches, offering valuable insights into region-specific drivers and therapeutic strategies.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 7","pages":"500-516"},"PeriodicalIF":51.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A sensory neuron–gastric cancer circuit 感觉神经元-胃癌回路

IF 51 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-04-04 DOI: 10.1038/s41575-025-01066-8

Eleni Kotsiliti

引用次数: 0

International collaborative research to improve gallbladder cancer prevention 加强胆囊癌预防的国际合作研究

IF 51 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-04-04 DOI: 10.1038/s41575-025-01061-z

Dominique Scherer, Rajiv Kumar, Justo Lorenzo Bermejo, on behalf of EULAT Eradicate GBC

引用次数: 0

Behavioural interventions increase uptake of CRC screening 行为干预增加了CRC筛查的接受度

IF 51 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-04-04 DOI: 10.1038/s41575-025-01064-w

Katrina Ray

引用次数: 0

Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations 东亚人群酒精相关肝病试验的遗传变异研究

IF 51 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-03-24 DOI: 10.1038/s41575-025-01060-0

Bossng Kang (, )

引用次数: 0

Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’ 回复“将遗传变异纳入东亚人群酒精相关肝病试验”

IF 51 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-03-24 DOI: 10.1038/s41575-025-01059-7

Mack C. Mitchell, Brian P. Lee, Jessica Mellinger, Laura E. Nagy

引用次数: 0

Cell therapy for liver disorders: past, present and future 肝脏疾病的细胞治疗：过去，现在和未来

IF 51 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-03-18 DOI: 10.1038/s41575-025-01050-2

M. Carmen Ortuño-Costela, Massimo Pinzani, Ludovic Vallier

{"title":"Cell therapy for liver disorders: past, present and future","authors":"M. Carmen Ortuño-Costela, Massimo Pinzani, Ludovic Vallier","doi":"10.1038/s41575-025-01050-2","DOIUrl":"10.1038/s41575-025-01050-2","url":null,"abstract":"The liver fulfils a plethora of vital functions and, due to their importance, liver dysfunction has life-threatening consequences. Liver disorders currently account for more than two million deaths annually worldwide and can be classified broadly into three groups, considering their onset and aetiology, as acute liver diseases, inherited metabolic disorders and chronic liver diseases. In the most advanced and severe forms leading to liver failure, liver transplantation is the only treatment available, which has many associated drawbacks, including a shortage of organ donors. Cell therapy via fully mature cell transplantation is an advantageous alternative that may be able to restore a damaged organ’s functionality or serve as a bridge until regeneration can occur. Pioneering work has shown that transplanting adult hepatocytes can support liver recovery. However, primary hepatocytes cannot be grown extensively in vitro as they rapidly lose their metabolic activity. Therefore, different cell sources are currently being tested as alternatives to primary cells. Human pluripotent stem cell-derived cells, chemically induced liver progenitors, or ‘liver’ organoids, hold great promise for developing new cell therapies for acute and chronic liver diseases. This Review focuses on the advantages and drawbacks of distinct cell sources and the relative strategies to address different therapeutic needs in distinct liver diseases. The burden of liver disorders increases worldwide as does the necessity for new treatments. This Review discusses cell therapy as an alternative therapeutic strategy for liver transplantation, the pros and cons, and the future technological potential.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"22 5","pages":"329-342"},"PeriodicalIF":51.0,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EASL Liver Cancer Summit 2025 EASL肝癌峰会2025

IF 45.9 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-03-12 DOI: 10.1038/s41575-025-01057-9

Jordan Hindson

引用次数: 0

Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment 作者更正：Μetabolic功能障碍相关的脂肪变性肝病：异质性代谢危险因素、机制和合并症的状况，需要整体治疗

IF 51 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-03-07 DOI: 10.1038/s41575-025-01056-w

Christopher D. Byrne, Angelo Armandi, Vanessa Pellegrinelli, Antonio Vidal-Puig, Elisabetta Bugianesi

引用次数: 0